Compare CD & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CD | CUVL |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Computer Software: Programming Data Processing | Miscellaneous |
| Sector | Technology | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 374.2M |
| IPO Year | 2014 | N/A |
| Metric | CD | CUVL |
|---|---|---|
| Price | $7.04 | $5.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 263.3K | 7.2K |
| Earning Date | 08-31-2023 | 08-27-2026 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,867,068.00 | N/A |
| Revenue This Year | N/A | $0.89 |
| Revenue Next Year | N/A | $6.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.93 | N/A |
| 52 Week Low | $2.10 | $4.91 |
| 52 Week High | $14.10 | $8.20 |
| Indicator | CD | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 55.42 | 35.18 |
| Support Level | $4.86 | N/A |
| Resistance Level | $8.89 | $6.04 |
| Average True Range (ATR) | 1.60 | 0.14 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 25.72 | 29.82 |
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.